Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

578
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
578
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.5K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.5K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

789
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
789

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dementia and Frailty Impact Postoperative Care Trajectories and Burden among Older Adults Undergoing Radical Cystectomy for Bladder Cancer.

medRxiv : the preprint server for health sciences·2026
Same author

Outcomes of isolated small bowel transplant-Initial experience from India.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology·2026
Same author

Drug-eluting Balloon Angioplasty as a Bridge to Early Liver Transplantation in Recipients with Coronary Artery Disease: A Case Series.

Journal of clinical and experimental hepatology·2026
Same author

Previous Abdominal Surgery Is Not Associated With Adverse Pregnancy, Delivery, or Neonatal Outcomes in Women With Crohn's Disease: Results From the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes Study.

The American journal of gastroenterology·2026
Same author

Impact of Hereditary Cancer Susceptibility in Solid-Organ Transplant Recipients.

JCO precision oncology·2026
Same author

Identifying domains for CNO and SAPHO: A scoping review to create domains from existing outcomes by the OMERACT CNO and SAPHO working group.

Seminars in arthritis and rheumatism·2025

Related Experiment Video

Updated: Mar 6, 2026

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery
07:12

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery

Published on: April 8, 2021

5.2K

Olmesartan-Induced Enteropathy.

Abimbola Adike1, Juan Corral2, David Rybnicek3

  • 1Houston Methodist Hospital, Houston, Texas.

Methodist Debakey Cardiovascular Journal
|March 15, 2017
PubMed
Summary
This summary is machine-generated.

Olmesartan-induced enteropathy shares symptoms with celiac disease but lacks elevated tissue transglutaminase and gluten response. Stopping olmesartan can resolve these sprue-like enteropathy symptoms.

Keywords:
celiac diseasediarrheaolmesartan-induced enteropathy

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.0K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K

Related Experiment Videos

Last Updated: Mar 6, 2026

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery
07:12

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery

Published on: April 8, 2021

5.2K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.0K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Pharmacology

Background:

  • Olmesartan is an angiotensin II receptor blocker used to treat hypertension.
  • Sprue-like enteropathy presents with symptoms similar to celiac disease, including diarrhea and weight loss.
  • Differential diagnosis of sprue-like enteropathy is crucial for appropriate patient management.

Observation:

  • Olmesartan-induced enteropathy clinically and pathologically resembles celiac disease.
  • Key pathological findings include villous atrophy and increased intraepithelial lymphocytes.
  • Symptoms include diarrhea, weight loss, and nausea, mirroring celiac disease presentations.

Findings:

  • Unlike celiac disease, tissue transglutaminase levels are not elevated in olmesartan-induced enteropathy.
  • Patients do not exhibit improvement on a gluten-free diet.
  • Discontinuation of olmesartan leads to clinical and histological resolution.

Implications:

  • Early diagnosis of olmesartan-induced enteropathy is critical.
  • Distinguishing it from celiac disease avoids unnecessary dietary restrictions.
  • Switching to an alternative antihypertensive medication simplifies diagnosis and treatment, improving patient outcomes.